ReviewGlucocorticoid receptors in major depression: relevance to pathophysiology and treatment
Introduction
Hyperactivity of the hypothalamic–pituitary–adrenal (HPA) axis in patients with major depression is one of the most consistent findings in biological psychiatry. Specifically, patients with major depression have been shown to exhibit increased concentrations of cortisol in plasma, urine, and cerebrospinal fluid (CSF); an exaggerated cortisol response to adrenocorticotropic hormone (ACTH); and an enlargement of both the pituitary and the adrenal glands Gold et al 1988, Holsboer and Barden 1996, Nemeroff 1996, Owens and Nemeroff 1993.
These HPA axis alterations are believed to be secondary to hypersecretion of corticotropin-releasing hormone (CRH), which has behavioral effects in animals that are similar to those seen in depressed patients, including alterations in activity, appetite, and sleep (Owens and Nemeroff 1993). Moreover, depressed patients exhibit increased concentrations of CRH in the CSF, increased CRH messenger RNA (mRNA) and protein in the paraventricular nucleus (PVN) of the hypothalamus (postmortem samples), and a blunted ACTH response to a CRH challenge (likely reflecting downregulation of pituitary CRH receptors) Gold et al 1988, Nemeroff 1996. Finally, downregulation of CRH receptors in the frontal cortex of victims of suicide (many of whom were presumably depressed) has been described (Nemeroff 1996).
Although the mechanism by which extrahypothalamic CRH is elevated in depression has not been resolved, the increased levels of CRH in the hypothalamus are thought to be related, in part, to altered feedback inhibition by endogenous glucocorticoids. Through binding to their receptors in HPA axis tissues, endogenous glucocorticoids serve as potent negative regulators of HPA axis activity including the synthesis and release of CRH in the PVN Owens and Nemeroff 1993, Reul and de Kloet 1985. Data supporting the notion that glucocorticoid-mediated feedback inhibition is impaired in major depression come from a multitude of studies demonstrating nonsuppression of cortisol secretion following administration of the synthetic glucocorticoid dexamethasone and more recent studies showing a lack of inhibition of ACTH responses to CRH following dexamethasone pretreatment Gold et al 1988, Heuser et al 1994, Holsboer and Barden 1996, Nemeroff 1996, Owens and Nemeroff 1993. Although nonsuppression to dexamethasone in the dexamethasone suppression test (DST) and the dexamethasone–CRH test likely represent impaired feedback inhibition at the level of the pituitary de Kloet 1998, Miller et al 1992, impaired responsiveness to hydrocortisone challenge in depressed patients suggests these feedback alterations also occur in the brain (Young et al 1991). Furthermore, the existence of reduced HPA axis suppression by dexamethasone in first-degree relatives of depressed individuals suggests that altered feedback inhibition may represent a genetic (trait) vulnerability to the depressive disorders (Modell et al 1998).
Feedback regulation of the HPA axis by glucocorticoids is mediated through two distinct intracellular receptor subtypes referred to as the mineralocorticoid receptor (MR) and the glucocorticoid receptor (GR) (Reul and de Kloet, 1985). The MR has a high affinity for endogenous corticosteroids and is believed to play a role in the regulation of circadian fluctuations in these hormones (especially the regulation of ACTH secretion during the diurnal trough in cortisol secretion). In contrast to the MR, the GR has a high affinity for dexamethasone and a lower affinity for endogenous corticosteroids. The GR is therefore believed to be more important in the regulation of the response to stress when endogenous levels of glucocorticoids are high. Recently, Spencer et al (1998) and de Kloet et al (1998) have clarified that GR activation is necessary for the HPA feedback regulation when levels of glucocorticoids are high (response to stress, circadian peak), but that the MR also plays an important role by modulating GR-dependent regulation. Because patients with major depression exhibit impaired HPA negative feedback in the context of elevated circulating levels of cortisol and because altered HPA axis responsiveness has been characterized with dexamethasone, which selectively binds GR in vivo, studies investigating corticosteroid receptors in major depression have logically focused on the expression and function of GR.
Section snippets
Glucocorticoid receptors in depression
Over the past 15 years a number of studies have assessed GRs in patients with major depression. In general, these studies have measured GR numbers directly or have examined the in vitro or in vivo influence of glucocorticoids on functions known to be regulated by the GR. These GR assessments have been made primarily on peripheral cell types including immune cells (mononuclear and polymorphonuclear leukocytes) and fibroblasts (gingival and skin). Limited information exists regarding the number
Mechanisms of glucocorticoid receptor resistance
Three major possibilities have been considered regarding the mechanism(s) of GR resistance in depression. These include: 1) GR downregulation secondary to persistent hypercortisolism, 2) a primary alteration in the genetic structure of the GR, and 3) a decrease in GR function secondary to alterations in ligand-independent pathways that regulate the GR (Bamberger et al 1996).
As previously discussed, the cytosolic and whole cell GR binding data do not provide a compelling case for GR
Impact of antidepressants on glucocorticoid receptor number and function
Perhaps the most striking support of the hypothesis that abnormalities in the GR contribute to the pathophysiology of major depression derives from studies suggesting that antidepressants may exert their clinical effects through direct modulation of the GR.
A number of animal studies have examined the impact of long-term in vivo treatment with tricyclic and nontricyclic antidepressants or electroconvulsive therapy on GR expression and glucocorticoid feedback inhibition Table 3, Table 4. These
Conclusions
Given the importance of glucocorticoids and the GR in the regulation of the HPA axis, it is logical to hypothesize that disruption of glucocorticoid action through altered functioning of the GR may be involved in the pathophysiology of major depression, a disorder that is characterized by HPA axis hyperactivity and CRH hypersecretion. Glucocorticoid resistance in depressed patients provides evidence of GR dysfunction, and data demonstrating GR regulation by steroid-independent factors that are
Acknowledgements
CMP is a United Kingdom Medical Research Council Clinical Training Fellow. This work was also supported by grants from the National Institute of Mental Health (Nos. MH00680 and MH47674) and the National Alliance for Research on Schizophrenia and Depression (van Ameringen Investigator) (AHM).
The authors thank Andrea Reemsnyder for her assistance with manuscript preparation.
References (98)
- et al.
The relationship of the dexamethasone suppression test (1 mg and 2 mg) to basal plasma cortisol levels in endogenous depression
Psychoneuroendocrinology
(1987) - et al.
Indole-pyruvic acid, a tryptophan ketoanalogue, antagonizes the endocrine but not the behavioral effects of repeated stress in a model of depression
Biol Psychiatry
(1993) - et al.
The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brainTherapeutic implications
Brain Res
(1992) - et al.
Cortisol suppression per nanogram per milliliter of plasma dexamethasone in depressive and normal subjects
Biol Psychiatry
(1988) - et al.
The novel antidepressant, tianeptine, reduces stress-evoked stimulation of the hypothalamo-pituitary-adrenal axis
Eur J Pharmacol
(1991) - et al.
Ligand-independent activation of the glucocorticoid receptor by Beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells
J Biol Chem
(1999) - et al.
Intracellular traffic of steroid hormone receptors
J Steroid Biochem Mol Biol
(1996) - et al.
The combined dexamethasone/CRH testA refined laboratory test for psychiatric disorders
J Psychiatr Res
(1994) - et al.
Lymphocyte glucocorticoid receptor binding in depressionNormal values following recovery
J Affect Disord
(1988) - et al.
Sickness behavior as a new target for drug development
Trends Pharmacol Sci
(1992)
Regulation of serotonin 1A, glucocorticoid and mineralocorticoid receptor in rat and human hippocampusImplications for the neurobiology of depression
Biol Psychiatry
Comparison of in vivo and in vitro glucocorticoid sensitivity in depressionRelationship to the dexamethasone suppression test
Biol Psychiatry
Relationship between interleukin-6 activity, acute phase proteins, and the function of the hypothalamic-pituitary-adrenal axis in severe depression
Psychiatry Res
Plasma sialyltransferase levels in psychiatric disorders as a possible indicator of HPA function
Biol Psychiatry
Glucocorticoid receptors are differentially expressed in the cells and tissues of the immune system
Cell Immunol
Adrenal steroid receptor activation in rat brain and pituitary following dexamethasoneImplications for the dexamethasone suppression test
Biol Psychiatry
An alternative ligand-independent pathway for activation of steroid receptors
Recent Prog Horm Res
Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain
Psychoneuroendocrinology
The role of heat shock proteins in regulating the function, folding, and trafficking of the glucocorticoid receptor
J Biol Chem
The effect of repeated combined treatment with nifedipine and antidepressant drugs or electroconvulsive shock on the hippocampal corticosteroid receptors in rats
Neuropharmacology
Disturbed glucocorticoid receptor autoregulation and corticotropin response to dexamethasone in depressives pretreated with metyrapone
Biol Psychiatry
Lymphocyte glucocorticoid receptor binding during depression and after clinical recovery
J Affect Disord
Heat shock induces translocation of the unliganded glucocorticoid receptor
J Biol Chem
Structural and functional reconstitution of the glucocorticoid receptor-hsp90 complex
J Biol Chem
Lymphocyte glucocorticoid receptor binding in depressed patients with hypercortisolemia
Psychoneuroendocrinology
Corticosterone regulation of type I and type II adrenal steroid receptors in brain, pituitary, and immune tissue
Brain Res
Increased intra-abdominal fat deposition in patients with major depression illness as measured by computed tomography
Biol Psychiatry
Regulation of glucocorticoid receptor-mRNA in human blood cells by amitriptyline and dexamethasone
J Psychiatr Res
Glucocorticoid receptor binding in three different cell types in major depressive disorderLack of evidence of receptor binding defect
Prog Neuropsychopharmacol Biol Psychiatry
Mononuclear leukocyte glucocorticoid receptor binding characteristics and down-regulation in major depression
Psychoneuroendocrinology
Decreased glucocorticoid receptor mRNA levels in individuals with depression, bipolar disorder and schizophrenia
Schizophr Res
Normal lymphocyte responsiveness to lectins but impaired sensitivity to in vitro glucocorticoids in major depression
J Affect Disord
Cell-mediated immunity and its glucocorticoid-sensitivity after clinical recovery from severe major depressive disorder
J Affect Disord
Glucocorticoids, hippocampal corticosteroid receptor gene expression and antidepressant treatmentRelationship with spatial learning in young and aged rats
Psychoneuroendocrinology
Glucocorticoid receptor number and cortisol excretion in mood, anxiety and psychotic disorders
Biol Psychiatry
Changes at multiple levels of the hypothalamo-pituitary adrenal axis following repeated electrically induced seizures
Psychoneuroendocrinology
Reduced G protein functions and immunoreactive levels in mononuclear leukocytes of patients with depression
Am J Psychiatry
Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids
Endocr Rev
Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain
J Clin Invest
Antidepressant drugs inhibit glucocorticoid receptor mediated gene transcription—a possible mechanism
Br J Pharmacol
The effect of chronic treatment with antidepressant drugs on the corticosteroid receptor levels in the rat hippocampus
Pol J Pharmacol
Chronic antidepressant treatment facilitates G protein activation of adenylyl cyclase without altering G protein content
J Pharmacol Exp Ther
Chronic treatment of C6 glioma cells with antidepressant drugs increases functional coupling between a G protein (Gs) and adenylyl cyclase
J Neurochem
Brain corticosteroid receptor balance in health and disease
Endocr Rev
Differential autoregulation of glucocorticoid receptor expression in human T- and B-cell lines
Endocrinology
Pulse-dosing and conventional application of doxepinEffects on psychopathology and hypothalamus-pituitary-adrenal axis
J Clin Psychopharmacol
Differential effects of chronic antidepressant treatment on swim stress and fluoxetine induced secretion of corticosterone and progesterone
J Pharmacol Exp Ther
Increased synaptic availability of norepinephrine following desipramine is not essential for increases in GR mRNA
J Neural Transm
Cited by (986)
The contribution of polyamine pathway to determinations of diagnosis for treatment-resistant depression: A metabolomic analysis
2024, Progress in Neuro-Psychopharmacology and Biological PsychiatrySex differences in cortisol levels in depression: A systematic review and meta-analysis
2024, Frontiers in NeuroendocrinologyEffects of Cortisol Administration on Resting-State Functional Connectivity in Women with Depression
2024, Psychiatry Research - Neuroimaging